O Neil Global Advisors Inc. Takes $10.93 Million Position in CRISPR Therapeutics AG $CRSP

O Neil Global Advisors Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 168,715 shares of the company’s stock, valued at approximately $10,934,000. CRISPR Therapeutics makes up about 2.0% of O Neil Global Advisors Inc.’s holdings, making the stock its 13th biggest position.

Other hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its holdings in CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after acquiring an additional 859,334 shares during the period. Orbis Allan Gray Ltd lifted its position in shares of CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock valued at $153,253,000 after purchasing an additional 66,556 shares during the period. Geode Capital Management LLC grew its holdings in shares of CRISPR Therapeutics by 98.1% in the second quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company’s stock valued at $100,789,000 after purchasing an additional 1,025,979 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in CRISPR Therapeutics by 98.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock worth $38,459,000 after buying an additional 294,222 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Pipeline and earnings reaction — MarketBeat notes investors cheered Q4 results for pipeline progress and CASGEVY adoption (cash runway ~ $1.9B, CTX611 upside). That optimism helped the stock rebound after earnings even though reported revenue was small due to revenue-sharing with Vertex. CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
• Positive Sentiment: Bull case on long-term upside — Seeking Alpha highlights a “Buy” thesis driven by CASGEVY launch economics and CTX611 potential (modeled high peak sales), arguing significant upside exists despite high risk. Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
• Neutral Sentiment: Short-interest data ambiguous — reported short interest entries show zero shares/NaN changes and a 0.0 days ratio, which appears to be a reporting artifact rather than meaningful positioning information. No clear short-squeeze or build-up signal.
• Neutral Sentiment: Reassessment pieces — coverage (Yahoo) asks whether the recent rebound warrants a rethink, reflecting mixed analyst views and technical levels to watch; useful for investors weighing timing. Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Share Price Rebound?
• Negative Sentiment: Insider selling — CEO Samarth Kulkarni and General Counsel James Kasinger sold shares on Feb 19 (CEO ~6,967 shares; GC ~2,112 shares), modestly reducing their positions. Insider sales can signal near-term caution to some investors. CEO Filing GC Filing
• Negative Sentiment: Near-term fundamentals and skepticism — Q4 showed a big EPS miss and revenue limited by a revenue-share with Vertex; some analysts (e.g., Morgan Stanley cited in coverage) remain cautious with low price targets. Pessimistic takes (Fool) question the long-term payoff versus risk. Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CRSP shares. Citigroup reissued a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th. Wedbush decreased their target price on CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, November 5th. Needham & Company LLC boosted their target price on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, February 13th. Robert W. Baird reduced their price target on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $64.24.

CRISPR Therapeutics Stock Performance

CRSP opened at $53.46 on Monday. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $78.48. The company has a market cap of $5.13 billion, a P/E ratio of -8.20 and a beta of 1.72. The business’s 50-day simple moving average is $53.84 and its 200-day simple moving average is $57.24.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business’s revenue for the quarter was down 97.8% compared to the same quarter last year. During the same period last year, the company earned ($1.01) earnings per share. As a group, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the transaction, the chief executive officer directly owned 134,201 shares of the company’s stock, valued at $8,082,926.23. This trade represents a 30.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,112 shares of CRISPR Therapeutics stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total transaction of $111,048.96. Following the sale, the general counsel owned 85,115 shares in the company, valued at $4,475,346.70. This represents a 2.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 99,079 shares of company stock valued at $5,643,674. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.